Bevacizumab biosimilar (Jiangsu Hengrui Medicine)

贝伐珠单抗生物类似药（江苏恒瑞医药）

Report date: 2026/05/13 14:41:00

Base Information

Drug NameBevacizumab biosimilar (Jiangsu Hengrui Medicine)
Drug Alias Name贝伐单抗生物仿制药（江苏恒瑞医药）贝伐珠单抗生物仿制药（江苏恒瑞医药）贝伐赛珠单抗生物仿制药（江苏恒瑞医药）贝伐人源化单抗生物仿制药（江苏恒瑞医药）艾瑞妥 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/22
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteFudan UniversitySuzhou Suncadia Biopharmaceuticals Co Ltd +[4] 
Inactive CompaniesShanghai Hengrui Pharmaceutical Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A